EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, WAVE Life Sciences's Enterprise Value is $451.7 Mil.
WAVE Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-20.5 Mil. Therefore, WAVE Life Sciences's EV-to-FCF for today is -21.99.
The historical rank and industry rank for WAVE Life Sciences's EV-to-FCF or its related term are showing as below:
WVE'
s EV-to-FCF Range Over the Past 10 Years
Min: -72.84 Med: -6.86 Max: 0.1
Current: -21.99
During the past 11 years, the highest EV-to-FCF of WAVE Life Sciences was 0.10. The lowest was -72.84. And the median was -6.86.
WVE's EV-to-FCF is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 4.22
vs WVE: -21.99
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), WAVE Life Sciences's stock price is $5.01.
WAVE Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.550. Therefore, WAVE Life Sciences's PE Ratio for today is At Loss.
WAVE Life Sciences EV-to-FCF Historical Data
The historical data trend for WAVE Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WAVE Life Sciences's EV-to-FCF
For the Biotechnology subindustry, WAVE Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's EV-to-FCF falls into.
WAVE Life Sciences EV-to-FCF Calculation
WAVE Life Sciences's EV-to-FCF for today is calculated as:
WAVE Life Sciences's current Enterprise Value is $451.7 Mil.
WAVE Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (NAS:WVE) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
WAVE Life Sciences's PE Ratio for today is calculated as:
WAVE Life Sciences's share price for today is $5.01.
WAVE Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
WAVE Life Sciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of WAVE Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
WAVE Life Sciences (WAVE Life Sciences) Business Description
WAVE Life Sciences Ltd is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WVE has been successfully added to your 